Alltrna, a tRNA therapy startup, received clearance to begin its first clinical trial, the company said. The trial launch marks a step into human testing for a platform approach in which a single tRNA-based therapy could be repurposed across multiple diseases. The announcement is notable because tRNA therapeutics are still early in clinical development relative to other RNA modalities, and first-in-human studies will be watched closely for dose selection, safety, and target biology. For the broader RNA therapeutics ecosystem, the entry adds another modality competing on manufacturability and repeatability of the therapeutic concept across indications.